Candel Therapeutics appoints Charles Schoch as Chief Financial Officer

Candel Therapeutics has entered into an employment agreement with Charles Schoch to serve as Chief Financial Officer effective June 12, 2026, with a base salary of $468,600 and target bonus of 40%. The appointment reflects the company's continued organizational development and financial leadership needs.